U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244614) titled 'Ustekinumab in BEhcet's Syndrome STudy' on Sept. 26.
Brief Summary: This non-interventional study is an observational cohort with parallel groups aiming primarily to describe the success of biosimilar of ustekinumab in Behcet's syndrome in whom conventional approaches have failed or are not suitable well tolerated, and then to compare with patients receiving apremilast within routine care.
Ustekinumab previously prescribed subcutaneously at 90 mg on Week 0, 4, 12 and 20 within the standard of care.
Following non-opposition to participate, patients data will be collected, which will comprise data of the 3-month interval medical vis...